Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of HCC, and analyses of liver samples from patients with NASH or NASH-related HCC show an elevated expression of the elongase ELOVL6 [10], which catalyzes the elongation of C16 to C18 fatty acids, and has been shown to promote NASH [11,12]. Here, ELOVL6 is linked to hepatocellular carcinoma.